{"id":2588,"date":"2023-10-29T12:00:00","date_gmt":"2023-10-29T04:00:00","guid":{"rendered":"https:\/\/www.junshipharma.com\/?p=2588"},"modified":"2024-01-03T18:34:59","modified_gmt":"2024-01-03T10:34:59","slug":"junshi-biosciences-announces-fda-approval-of-loqtorzi-toripalimab-tpzi-in-all-lines-of-treatment-for-recurrent-or-metastatic-nasopharyngeal-carcinoma-npc","status":"publish","type":"post","link":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-fda-approval-of-loqtorzi-toripalimab-tpzi-in-all-lines-of-treatment-for-recurrent-or-metastatic-nasopharyngeal-carcinoma-npc\/","title":{"rendered":"Junshi Biosciences Announces FDA Approval of LOQTORZI\u2122 (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)"},"content":{"rendered":"\n